Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $18.75.

A number of analysts have issued reports on KLRS shares. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, June 14th. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday, May 13th. TD Cowen assumed coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They issued a “buy” rating for the company. Morgan Stanley began coverage on shares of Kalaris Therapeutics in a report on Thursday, April 16th. They issued an “overweight” rating and a $14.00 target price for the company. Finally, Weiss Ratings cut shares of Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th.

Kalaris Therapeutics Trading Down 3.0%

Shares of KLRS stock opened at $4.19 on Thursday. Kalaris Therapeutics has a 12-month low of $2.14 and a 12-month high of $11.88. The stock’s 50-day moving average price is $4.35 and its 200-day moving average price is $6.39. The stock has a market capitalization of $99.68 million, a price-to-earnings ratio of -1.95 and a beta of 0.20.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. As a group, research analysts predict that Kalaris Therapeutics will post -2 EPS for the current fiscal year.

Insider Activity at Kalaris Therapeutics

In other Kalaris Therapeutics news, Director Srinivas Akkaraju acquired 244,300 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $4.83 per share, with a total value of $1,179,969.00. Following the purchase, the director directly owned 2,224,147 shares of the company’s stock, valued at approximately $10,742,630.01. This represents a 12.34% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 68.10% of the stock is owned by insiders.

Institutional Trading of Kalaris Therapeutics

Several hedge funds have recently made changes to their positions in the business. WHI TRUST Co LLC bought a new position in shares of Kalaris Therapeutics in the 4th quarter valued at about $823,000. Barclays PLC purchased a new position in Kalaris Therapeutics in the fourth quarter worth about $51,000. Walleye Capital LLC bought a new stake in Kalaris Therapeutics during the fourth quarter worth approximately $95,000. State Street Corp increased its stake in Kalaris Therapeutics by 12.4% during the fourth quarter. State Street Corp now owns 25,410 shares of the company’s stock worth $214,000 after acquiring an additional 2,800 shares during the last quarter. Finally, Keel Point LLC purchased a new stake in Kalaris Therapeutics during the fourth quarter valued at approximately $86,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.